Home › Research › Treatments
The Evolution of Randomized Clinical Trial Designs to Assess Therapeutics in Alzheimer Disease
Aumont E, Therriault J, Kwan ATH, Carello-Collar G, Arfaie S, Hall BJ, Ferrari-Souza JP, Woo MS et al.. JAMA network open, 2025-08-01
Topic: Amyloid, tau and blood-test diagnosis
Results The study included 203 RCTs with 79 589 participants testing interventions in AD. A substantial difference in the type of therapeutics researched was observed, with anti-amyloid and anti-tau RCTs being more likely to be funded by the pharmaceutical industry compared with neurotransmitter or other RCTs (anti-amyloid or anti-tau, 68 of 71 [95.8%]; neurotransmitter, 52 of 69 [77.6%]; other, 33 of 52 [63.5%]).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Aumont, E., Therriault, J., Kwan, A. T. H., Carello-Collar, G., Arfaie, S., Hall, B. J., et al. (2025). The Evolution of Randomized Clinical Trial Designs to Assess Therapeutics in Alzheimer Disease. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2025.29665
Vancouver
Aumont E, Therriault J, Kwan ATH, Carello-Collar G, Arfaie S, Hall BJ, et al. The Evolution of Randomized Clinical Trial Designs to Assess Therapeutics in Alzheimer Disease. JAMA network open. 2025. doi:10.1001/jamanetworkopen.2025.29665. PMID: 40880087.
BibTeX
@article{aumont2025-40880087,
author = {Aumont, E. and Therriault, J. and Kwan, A. T. H. and Carello-Collar, G. and Arfaie, S. and Hall, B. J. and Ferrari-Souza, J. P. and Woo, M. S. and others},
title = {{The Evolution of Randomized Clinical Trial Designs to Assess Therapeutics in Alzheimer Disease}},
journal = {JAMA network open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.29665},
pmid = {40880087},
url = {https://doi.org/10.1001/jamanetworkopen.2025.29665}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results The study included 203 RCTs with 79 589 participants testing interventions in AD.
- A substantial difference in the type of therapeutics researched was observed, with anti-amyloid and anti-tau RCTs being more likely to be funded by the pharmaceutical industry compared with neurotransmitter or other RCTs (anti-amyloid or anti-tau, 68 of 71 [95.8%]; neurotransmitter, 52 of 69 [77.6%]; other, 33 of 52 [63.5%]).
Why it matters
This study analyzed 203 past Alzheimer's trials and found that anti-amyloid and anti-tau trials were more likely to be funded by the pharmaceutical industry than other types of trials. It does not report whether any treatment worked, only how trial funding and design have changed over time.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants203
- Effect sizeincreased by 464%; increased by 188%; 2.7%
- Evidence strengthHigh
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA network open) |
| Journal's citation record | 2 / 4 | JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 203 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Pedro Rosa‐Neto: h-index 89 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Berkeley: institution h-index 2,012 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40880087) |
| Free to read | 2 / 2 | Free to read |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamanetworkopen.2025.29665
- PubMed: 40880087
- Original source →
- Free full text: JAMA Network Open →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.